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Highlights:
	We performed a genome-wide association study (GWAS) of suicide behavior severity.
	Our GWAS was conducted in three samples of bipolar disorder patients.





Suicide claims 1 million lives each year worldwide, and for each completed suicide, there are twenty suicide attempts, making it an important public health issue.  Over 90% of suicide victims have at least one psychiatric diagnosis, including bipolar disorder (BD) (), where as much as 8% of BD followed for up to 40 years committed suicide  ADDIN EN.CITE (; ). 
Suicide has a prominent genetic component (reviewed in ()).  Suicide attempts tend to occur more often within families  ADDIN EN.CITE (; ).  Greater concordance was observed between monozygotic twins than between dizygotic twins  ADDIN EN.CITE (; ).  The concordant phenotype includes both completed and attempted suicides (Roy et al, 1995).  A review of twin studies estimated the heritability of suicidal behaviour to be up to 55% ().
A number of linkage studies have been conducted on suicide starting with Zubenko and coworkers  ADDIN EN.CITE ().  Their findings on the short arm of chromosome 2 were later replicated in 162 BD families  ADDIN EN.CITE (), and more recently confirmed in the regional linkage study meta-analysis of 2p12  ADDIN EN.CITE ().  Recent technological advances have permitted the high-throughput genotyping of hundreds of thousands of single-nucleotide polymorphisms across the genome.  While no genome-wide significant findings (at significance levels of less than 5x10-8) have been reported to date, a number of suggestive findings have emerged  ADDIN EN.CITE (; ).  Recently, a genome-wide association study (GWAS) was reported on samples of 2698 BD patients of which 1201 had a previous suicide attempt.  After meta-analysis of markers with p<1x10-3 from their discovery sample (GAIN, TGEN, German) with their replication BD sample (STEP-BD, WTCCC, UCL), the most significantly associated marker was rs300774 in an intergenic region at chromosomal region 2p25, which contains the SH3YL1, ACP1, and FAM150B genes.  The association finding was supported by post-mortem prefrontal cortical gene expression analysis, where suicide completers were found to have significantly higher ACP1 expression than non-suicide victims  ADDIN EN.CITE ().  The strongest association signal from another report of a GWAS of suicide attempt on the BD (STEP-BD, WTCCC, UCL) came from the intergenic chromosome 10 marker rs1466846; this finding was not replicated in the replication sample (GAIN, TGEN, German) (Perlis et al, 2010).  Part of the reason for both lack of a strong association signal and robust replication could be that the samples are underpowered for analysis due to dichotomizing of the suicide attempt as the outcome variable.  A GWAS on suicidality scores, which are derived from the Schedule for Clinical Assessment in Neuropsychiatry (SCAN) interview, was conducted with a major depression sample from the RADIANT study  ADDIN EN.CITE ().  The suicidality score captures suicide severity from suicide ideation to attempt.  The most significant findings from the RADIANT sample failed to replicate in the German replication sample.    






The characteristics of the samples included in this study have been described previously  ADDIN EN.CITE (; ).  For the first sample, two hundred and twelve small nuclear families (Sample CA1) were recruited at the Centre for Addiction and Mental Health (CAMH) in Toronto, Canada.  Suicidality was assessed using the semi-structured interview for DSM-IV, with the Suicide Specifier Score: 0 for non-suicidal, 1 for having thoughts of own death, 2 for having suicidal ideation, 3 for having planned suicide, and 4 having attempted suicide (Supplementary Figure 1a).  We also recruited a second independent sample consisting of 428 BD patients (Sample CA2) at CAMH, and a third sample of 483 BD cases (Sample IOP) from the Institute of Psychiatry in London, UK.  Details on the CA2 and IOP samples have been described previously  ADDIN EN.CITE ().  The participants were at least 18 years of age at time of enrolment and European ancestry by self-report.  They were recruited through advertisements in family doctors’ offices, clinics, hospitals, and patient support groups.  Their diagnoses for BD according to DSM-IV and ICD-10 criteria were confirmed using the Schedules for Clinical Assessment in Neuropsychiatry (SCAN). Exclusion criteria included a diagnosed or reportedis of dependence on intravenous drugs dependency, reported intravenous drug use, the presence of mood incongruent psychotic featuresymptoms, and the presence of manic episodes that are only in conjunctionconcurrent with or as a result of alcohol, substance abuse, substance or dependence, medication, or medical conditionillnesses, or medication.  Their suicidality was assessed using the Suicide Severity item within the Schedules for Clinical Assessment in Neuropsychiatry (SCAN) as follows: 0 for non-suicidal, 1 for deliberately considering suicide or self-harm, 2 for injuring self or making an attempt without serious consequences; 3 for serious self-harm or attempt; 4 for an attempt at suicide designed to be lethal (Supplementary Figures 1b and 1c).  More details on sample characteristics are shown in Table 1.  All procedures contributing to this work abide by the Declaration of Helsinki in 1975 (revised in 2008), and the ethical standards of the national and institutional committees on human experimentation.
Sample CA1 was genotyped with the Affymetrix 5.0 arrays (Affymetrix, Santa Clara, CA, USA) at the London Regional Genomics Centre (London, Ontario, Canada).  Samples CA2 and IOP were genotyped with the IlluminaSentrix Human Hap550 Beadchip (Illumina Inc., San Diego, CA, USA) mostly at Illumina Inc. (San Diego, CA, USA), with 290 subjects from the CA2 sample being genotyped at the Genome Quebec facility (Montreal, Quebec, Canada).  
We applied the same quality control measures for all three samples separately using PLINK () and R (R Development Core Team (2008). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-07-0, URL http://www.R-project.org.).  Briefly, individuals with less than 95% of the markers genotyped were removed, and markers that were less than 95% genotyped or had a minor allele frequency of less than 5% were excluded.  Cryptic relatedness was assessed and one individual of each pair of related individuals (defined as pairs with PI^HAT>0.05) was removed if there is more missing phenotype or genotype information for that individual.  Sex was matched with genetic data.  Mean heterozygosity was determined, and outliers were removed.  Markers of which genotypes deviated significantly from Hardy-Weinberg Equilibrium (p<0.0001) were excluded from subsequent analyses.  We ran a multi-dimensional scaling (MDS) analysis of the genotypes to ascertain the ethnicity of the samples, and we removed the discrete cluster that corresponded to the self-reported Jewish ancestry for all four grandparents.  After sample refinement and updating map position to build 37, 209,824 markers remained for 543 CA1 cases in 189 small nuclear families, 438,625 markers for 308 CA2 cases, and 439,032 markers for 462 IOP cases.  Our total sample has enough power to detect 4% of the variance of suicide severity that is accounted for by the single-nucleotide polymorphism (SNP; alpha=5e-8, additive model)().
We conducted whole-genome imputation using IMPUTE2 () in 5-Mb segments after prephasing in SHAPEIT2 () for all three samples separately  using the 1000 Genome Project  ADDIN EN.CITE () build 37 macGT1 (Haplotype release date: March 2012) data as reference.  Then we converted the output to PLINK format using GTOOL (Genetics Software Suite, © 2007, The University of Oxford) with an imputation score threshold of 0.9.  Afterwards, we performed quantitative analyses on the suicide severity variables (qfam algorithm on suicide specifier for CA1, and linear regression on suicide severity for both CA2 and IOP) in PLINK.  The qfam algorithm adopts the within/between model  ADDIN EN.CITE (; ) and uses permutation to account for related individuals.  We included age, sex, past alcohol dependence/abuse, the number of depressive episodes, and the first two components from the multidimensional scaling (MDS) analysis as covariates.  To compare our findings with those of previous suicide GWAS  ADDIN EN.CITE (), we also performed analyses on suicide attempt history (tdt for CA1 -- with patients scoring 4 or above on the SCID Suicide Specifier classified as suicide attempters, and logistic regression for CA2 and IOP – with patients scoring 2 or above on the SCAN Suicide Severity item) in PLINK.  Thus our suicide attempters included patients who have had non-suicidal self injury.  For markers that are included in all three samples, we performed a meta-analysis using sample size, direction of effect, and p value to derive an overall p-value for each marker (METAL software ()).  The quantile-quantile plots and the Manhattan plots were drawn in R.

RESULTS
We found 2,659,407 markers to be common across all three samples after imputation with the 1000 Genome Project data.  With these 2.66 million markers, we ran a meta-analysis for which the results are summarized in Figure 1 (quantile-quantile plot: genomic inflation value (lambda) = 0.99) and Figure 2 and S2 (Manhattan plot). 
We found markers in two chromosomal regions to have suggestive associations with suicide severity (Supplementary Table 1: 41 markers with uncorrected p<1e-5; Table 2a: 14 markers with uncorrected p<5e-6).  The first region of interest resides within chromosome 8q12, close to the long intergenic non-protein coding RNA gene LINC00968 and the proenkephalin gene PENK (Figure 3a).  The second stretch is located at chromosomal location 10p11.2, which encompasses the genes CCDC7 (coiled-coil domain containing 7), C10orf68 (chromosome 10 open reading frame 68), and ITGB1 (integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen CD29 includes MDF2, MSK12)) (Figure 3b).  The minor allele frequencies of the top markers in our study mirrored those of the European sample from the 1000 Genome Project (Supplementary Table 1).  We also examined the markers that were directly genotyped in the regions harbouring the suggestive associations and found a number of nominal associations in these chromosomal regions for each of the three samples (uncorrected p<0.05; Supplementary Table 2).
In addition to GWAS of suicide severity, we also performed a GWAS of suicide attempt in our three BD samples (Table 2b: four markers with uncorrected p<5e-6).  Two regions of suggestive associations were found (Supplementary Figure S2).  The first was localized to 8q12-q21 and was approximately 400kb upstream of the interleukin 7 (IL7) gene.  The second was approximately 150kb downstream of the thioredoxin-related transmembrane protein 3 coding TMX3 gene in 18q22.  We further compared findings from our meta-analysis of suicide attempt (yes/no) with the top findings (2507 markers) from a recent GWAS of suicide attempt in BD where the p-values were less than 0.001 for the pooled discovery sample consisting of the GAIN, TGEN, German subsamples  ADDIN EN.CITE ().  None of the 1,210 SNPs that overlap between our meta-analysis samples and the discovery sample from the Willour et al (2012) study had p values of less than 1e-5. Nonetheless, 47 SNPs across our meta-analysis samples had uncorrected p values of less than 0.05 from our meta-analysis, the Willour discovery sample, and the Willour replication sample that consisted of the STEP-BD, WTCCC, and UCL subsamples (Supplementary Table 3).  All 47 SNPs are located in the Signal-induced proliferation-associated 1-like protein 1 gene SIPA1L1 on chromosome 14q24.1.

DISCUSSION
We report here interesting findings in two chromosomal regions from the first GWAS meta-analysis of suicide severity in BD patients.  
The region of interest on chromosome 8 is located 5’ of the PENK gene that codes for an opioid polypeptide hormone proenkephalin.  The PENK protein is expressed in most tissues including the central nervous system, with the highest expression in the caudate nucleus, putamen, central nucleus, and nucleus accumbens.  Genetic mouse models have implicated PENK in regulating anxious and freezing behaviours  ADDIN EN.CITE ().  It may also play a role in regulating anxious and depressive behaviours after exposure to stress  ADDIN EN.CITE ().  Consequently, adding information on childhood trauma history may help to reduce the heterogeneity within the samples and address part of the mixed findings reported thus far.  With regard to functional evidence, conditional genetic ablation of the ITGB1 gene (on chromosome 10) resulted in defective cortical lamination during development and deficient long-term potentiation  ADDIN EN.CITE (). The function of CCDC7 is unknown, but its expression in the brain appears to be highest in the globus pallidus and corpus callosum (Allen Brain Atlas; ()).
We also found two chromosomal regions of potential interest from our GWAS of suicide attempt in our BD patients.  Interleukin 7 has been shown to augment neuronal differentiation  ADDIN EN.CITE (; ).  It is expressed in the brain, with the highest expression in the hypothalamus.  Its expression in the hypothalamus also matches its purported role in the regulation of feeding behaviour and body weight ().  TMX3 has the highest expression in the hypothalamus, but its role in this part of the brain has not been explored.
The gene we found interesting in comparison of our results of suicide attempt to results from previous GWASs, SIPA1L1, is expressed in the brain, with the highest expression in the dentate gyrus.  Further investigation of this gene may be warranted.
It is possible that the genetic susceptibility for suicidal behaviour may overlap across psychiatric diagnoses.  For instance, Perlis et al (2010) conducted a meta-analysis of markers with p<1x10-3 across two BD and two major depressive disorder pooled samples, and found half of the ten most significant markers to reside in the sorbin and SH3-domain containing-1 (SORBS1) gene.  SORBS1 has been implicated in insulin signalling.  Our results with SORBS1 were not significant (p>0.05; data not shown).  Our analysis of the ACP1 markers, the key finding in the Willour et al (2012) study, did not yield significant results (p>0.05; data not shown).  We  markers that were overlapping between two different genotyping platforms
The effect of psychotropic medication is an important confounder in suicide genetic studies.  Three GWAS of treatment-enhanced or –emergent suicidality have been carried out in large major depression samples  ADDIN EN.CITE (; ; ).  However, it is important to note that high suicidality is often an exclusion criteria for these longitudinal studies due to safety issues, making these study samples somewhat biased for the purpose of studying the lifetime history of suicide attempt and limited in their comparability with other studies on suicide attempt history.  It is important to note that the suicide severity phenotype we examined corresponds to current or the most serious depressive episode, while previous GWASs of suicide  ADDIN EN.CITE (; ) were in regards to lifetime history of suicide attempt.  Although most suicide attempts in bipolar disorder occur during the depressive phase, we might have missed a few mixed-state suicide attempters (Valtonen et al, 2007).  In addition, for our analysis of suicide attempt, the suicide attempter cases would have included individuals who have a history of non-suicidal self injury, as non-suicidal self injury can be a strong predictor of future suicide attempt  ADDIN EN.CITE (; ). , Tthus, our findings may not be directly comparable to previously published GWASs.
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Table 2(a).  Suggestive results (p<5e-6) from meta-analysis of the results from GWAS of suicide behaviour severity in our three bipolar disorder samples.  The results for each of the three samples are also shown.  All the markers shown were imputed.  Allele 2 is the test allele.

















Table 2(b).  Suggestive results (p<5e-6) from meta-analysis of the results from GWAS of suicide attempt in our three bipolar disorder samples.  The results for each of the three samples are also shown.    All the markers shown were imputed.  Allele 2 is the test allele.
		Sample CA1	Sample CA2	Sample IOP			

























Figure 3b.  LocusZoom plot showing the chromosome 10 region with the most significant markers from the genome-wide meta-analysis of suicide severity.














